Radiation Oncology | |
Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease | |
Phuoc T Tran1  Billy W Loo4  Edward E Graves4  Andrew Quon2  Richard T Hoppe4  Sandra Horning3  Ranjana Advani3  Zheng Su5  Leelanand P Rachakonda4  Diane Tseng4  | |
[1] Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutes, 1550 Orleans St., CRB2, Baltimore, MD 21231 USA;Department of Radiology, Stanford University School of Medicine, 300 Pasteur Dr., Stanford, CA, 94305 USA;Department of Medicine, Medical Oncology, Stanford University School of Medicine, 875 Blake Wilbur Dr., Stanford, CA, 94305 USA;Department of Radiation Oncology, Stanford University School of Medicine, 875 Blake Wilbur Dr., Stanford, CA 94305 USA;Department of Health Research and Policy, Biostatistics, Stanford University School of Medicine, 300 Pasteur Dr., Stanford, CA 94305 USA | |
关键词: survival; quantitative PET parameters; metabolic tumor volume; PET; Hodgkin's disease; | |
Others : 1160911 DOI : 10.1186/1748-717X-7-5 |
|
received in 2011-11-24, accepted in 2012-01-19, 发布年份 2012 | |
【 摘 要 】
Purpose
We hypothesized that quantitative PET parameters may have predictive value beyond that of traditional clinical factors such as the International Prognostic Score (IPS) among Hodgkin's disease (HD) patients.
Methods
Thirty HD patients treated at presentation or relapse had staging and interim-treatment PET-CT scans. The majority of patients (53%) had stage III-IV disease and 67% had IPS ≥ 2. Interim-treatment scans were performed at a median of 55 days from the staging PET-CT. Chemotherapy regimens used: Stanford V (67%), ABVD (17%), VAMP (10%), or BEACOPP (7%). Hypermetabolic tumor regions were segmented semiautomatically and the metabolic tumor volume (MTV), mean standardized uptake value (SUVmean), maximum SUV (SUVmax) and integrated SUV (iSUV) were recorded. We analyzed whether IPS, absolute value PET parameters or the calculated ratio of interim- to pre-treatment PET parameters were associated with progression free survival (PFS) or overall survival (OS).
Results
Median follow-up of the study group was 50 months. Six of the 30 patients progressed clinically. Absolute value PET parameters from pre-treatment scans were not significant. Absolute value SUVmax from interim-treatment scans was associated with OS as determined by univariate analysis (p < 0.01). All four calculated PET parameters (interim/pre-treatment values) were associated with OS: MTVint/pre (p < 0.01), SUVmeanint/pre (p < 0.05), SUVmaxint/pre (p = 0.01), and iSUVint/pre (p < 0.01). Absolute value SUVmax from interim-treatment scans was associated with PFS (p = 0.01). Three calculated PET parameters (int/pre-treatment values) were associated with PFS: MTVint/pre (p = 0.01), SUVmaxint/pre (p = 0.02) and iSUVint/pre (p = 0.01). IPS was associated with PFS (p < 0.05) and OS (p < 0.01).
Conclusions
Calculated PET metrics may provide predictive information beyond that of traditional clinical factors and may identify patients at high risk of treatment failure early for treatment intensification.
【 授权许可】
2012 Tseng et al; licensee BioMed Central Ltd.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20150411083750550.pdf | 859KB | download | |
Figure 3. | 33KB | Image | download |
Figure 2. | 19KB | Image | download |
Figure 1. | 55KB | Image | download |
【 图 表 】
Figure 1.
Figure 2.
Figure 3.
【 参考文献 】
- [1]Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478-1484.
- [2]Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A: The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006, 91:475-481.
- [3]Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen AM, Berthelsen AK, Specht L: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107:52-59.
- [4]Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007, 25:3746-3752.
- [5]GNU Project, The Comprhensive R Archive Network. R 2.5.1 [http://cran.r-project.org/] webciteInstitute for Statistics and Mathematics of the WU Wien;
- [6]Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999, 94:429-433.
- [7]Jerusalem G, Warland V, Najjar F, Paulus P, Fassotte MF, Fillet G, Rigo P: Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999, 20:13-20.
- [8]Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK: Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998, 25:721-728.
- [9]Kostakoglu L, Goldsmith SJ: Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000, 27:1564-1578.
- [10]O'Doherty MJ, Macdonald EA, Barrington SF, Mikhaeel NG, Schey S: Positron emission tomography in the management of lymphomas. Clin Oncol (R Coll Radiol) 2002, 14:415-426.
- [11]Schiepers C, Filmont JE, Czernin J: PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003, 30(Suppl 1):S82-88.
- [12]Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hänel A, Bredow J, Kühnel G, Kropp J, Hänel M, Laniado M, Kotzerke J, Ehninger G: Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004, 90:620-625.
- [13]Cheson BD: The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am 2007, 21:841-54.
- [14]Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ: Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 2007, 25:3902-3907.
- [15]Grow AQE, Loo BW Jr: Metabolic tumor volume as an independent prognostic factor in lymphoma [Abstract 6594]. Journal of Clinical Oncology 2005, 23:583S.
- [16]Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20:630-637.
- [17]Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billett AL, Marcus KC, Hurwitz CA, Young JA, Tarbell NJ, Weinstein HJ: VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol 2002, 20:3081-3087.
- [18]Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rüffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Dühmke E, Georgii A, Loeffler M: BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1998, 9(Suppl 5):S67-71.
- [19]Lee PWD, Lavori P, Quon A, Hara W, Maxim P, Le QT, Wakelee H, Donington J, Graves E, Loo BW: Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiation Oncology Biol Phys 2007, 69:328-333.
- [20]GraphPad: Kaplan-Meier Analysis. In GraphPad Prism version 4.0a for Macintosh ed. San Diego, California; 2003.
- [21]Advani RH, Hoppe RT, Maeda LS, Baer DM, Mason J, Rosenberg SA, Horning SJ: Stage I-IIA Non-bulky Hodgkin's Lymphoma. Is Further Distinction Based on Prognostic Factors Useful? The Stanford Experience. Int J Radiat Oncol Biol Phys 2010.